ReviewScientific reports2025
The role of SMARCA4 in lung cancer.
Review in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboringAnnals of medicine · 2026Article
- Identification of Potential Exosomal miRNA-mRNA Regulatory Network Relevant to Tuberculous-Associated Lung Cancer.Biomedicines · 2026Article
- Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report.Translational lung cancer research · 2026Article
- AI-Driven Combination Therapy for Counteracting Dysregulated Genes in Lung Adenocarcinoma: Contribution-Aware Metaheuristic for Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2026Article
- SMARCA4-deficient lung adenocarcinoma with oral cavity metastasis: a case report.BMC oral health · 2026Article
- SMARCA4-deficient non-small cell lung cancer and immunotherapy resistance: mechanisms and novel strategies-a mini-review.Discover oncology · 2026Review
- Analysis of clinical and genomic features in a Chinese cohort withTranslational lung cancer research · 2026Article
- CT imaging features of pulmonary SMARCA4-deficient undifferentiated carcinoma: a retrospective case series.Frontiers in oncology · 2026Article
- Case Report: Synaptophysin-positive SMARCA4-deficient undifferentiated thoracic tumour: a diagnostic pitfall with therapeutic implications.Frontiers in oncology · 2026Article
- Rare tongue base metastasis from SMARCA4-deficient undifferentiated non-small cell lung carcinoma: a case report.International journal of clinical and experimental pathology · 2026Article
- Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study.Frontiers in immunology · 2026Article
- Clinicopathological and Genomic Analysis ofCancer management and research · 2026Article
- SMARCA2 is an essential and potent cofactor for a specific subset of the glucocorticoid response in A549 cells.bioRxiv : the preprint server for biology · 2025Article
- Advances in Computational Drug Repurposing, Driver Genes, and Therapeutics in Lung Adenocarcinoma.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lung cancer remains one of the leading causes of mortality among cancer patients. Chromatin remodeling is a crucial epigenetic process in cancer, primarily regulated by alterations in genes encoding subunits of the switch/sucrose non-fermentable (SWI/SNF) complex. SMARCA4 and SMARCA2 are two mutually exclusive catalytic subunits within the SWI/SNF complex responsible for utilizing ATP hydrolysis to provide energy for chromatin remodeling. In lung cancer, SMARCA4 is one of the most common mutated subunits of the SWI/SNF complex. Patients with SMARCA4-deficient lung cancer typically experience poorer clinical outcomes. At present, there is no established targeted therapy designed specifically for this type of cancer. Here, we mainly discuss the mechanisms of SMARCA4 in lung cancer development and progression, its co-mutations and mutually exclusive mutations, cellular origin, clinical pathological characteristics, diagnosis and treatment of SMARCA4-deficient lung cancer. We also investigate the concept of synthetic lethality between SMARCA4 and SMARCA2, along with susceptibility to SMARCA4-deficient lung cancer and potential applications of immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.